Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo

Clinical trial NCT02509494 · COMPLETED

Trial details

NCT number: NCT02509494
Sponsor: Janssen Vaccines & Prevention B.V.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Ebola Virus Disease

Start date: 2015-09-30
Primary completion: 2019-06-28
Enrollment: 1023

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.